Noul Co Ltd

KRX • Healthcare • Diagnostics & Research • Quote as of 10/30/2026

Company Profile

IndustryDiagnostics & Research

SectorHealthcare

ExchangeKRX

Market Capitalization18,014 mln

Float9.66 mln

Piotroski F-Score

5 / 9

Neutral

Beneish M-Score

-2.42

Borderline

Relative Strength

98 / 100

Top performer

Debt / Equity

0.24

Very low leverage

Pre-Tax Margin

-538%

Severely loss-making

ROE

-122

Deeply negative

Business Description

Founded in 2015 and based in Yongin-si, South Korea, Noul Co. Ltd. develops and sells medical diagnostic technology across global markets. The company's main product, miLab, is an AI-powered device that handles blood testing automatically, from preparing samples to producing results. Noul also offers a range of diagnostic services covering areas such as malaria detection, blood cell examination, cancer analysis, and cervical cell screening.

Key Fundamentals

EPS-2,028

ROE-122

RPS408

ROIC-120

ROA-65.59

EBITDA, mln-16,841

EV / EBITDA-0.56

EV / EBIT-0.48

Revenue, mln3,658

EV / Revenue2.56

Quote Details

Last 1,657.00

Change 27 (1.66%)

Open 1,680.00

Volume 1,311,238

Turnover 2,172,721,408

Average Volume 603,614

Financial Ratios

Pre-Tax Profit Margin-538

Current Ratio4.10

Price / Book0.94

Price / Tangible Book1.10

Debt / Equity0.24

Price / Sales3.92

Financial Strength

Altman Z-Score-6.86

Piotroski F-Score 5 / 9

Beneish M-Score-2.42

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-0.78%	59 / 100
1 Month	6.63%	93 / 100
2 Months	-52.25%	1 / 100
6 Months	-78.85%	1 / 100
1 Year	-88.8%	0 / 100